Significance of Platelet-activating Factor Acetylhydrolase in Patients with Non-insulin-dependent (type 2) Diabetes Mellitus

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2003 Mar 4

PMID 12611648

Citations 12

Authors

M Serban

Cristina Tanaseanu

T Kosaka

Cristina Vidulescu

Irina Stoian

Daciana S Marta

S Tanaseanu

Elena Moldoveanu

Affiliations

Soon will be listed here.

Abstract

Background: Non-insulin dependent diabetes mellitus (NIDDM) represents an independent risk factor for cardiovascular diseases (CVD), being characterized by a continuous low-grade inflammation and endothelial activation state. Plasma platelet - activating factor - acetylhydrolases (PAF-AHs) are a subgroup of Ca(2+)-independent phospholipase A(2) family (also known as lipoprotein-associated phospholipases A(2)) that hydrolyze and inactivate the lipid mediator platelet-activating factor (PAF) and/or oxidized phospholipids. This enzyme is considered to play an important role in inflammatory diseases and atherosclerosis. The present study aims to investigate the relations between the levels of PAF-AH activity and LDL-cholesterol / HDL-cholesterol (LDL-ch / HDL-ch) ratio in NIDDM patients as compared to controls.

Methods: serum PAF-AH activity was measured in 50 patients with dyslipidemia, in 50 NIDDM patients and in 50 controls (normal lipid and glucose levels). Total cholesterol, LDL-ch, HDL-ch, triglyceride and blood glucose were determined in all subjects.

Results: All NIDDM patients display hiperlipidemia, with increased LDL-ch and triglyceride levels. There is a significant correlation between LDL-ch levels (especially LDL-ch / HDL-ch ratio) and PAF-AH activity in dyslipidemic and NIDDM patients.

Conclusion: Diabetic and dyslipidemic patients have an increased plasma PAF-AH activity correlated with their LDL-ch levels and mainly with LDL-ch / HDL-ch ratio. Plasma PAF-AH high levels appear to be important as a risk marker for endothelial dysfunction in patients with NIDDM.

Citing Articles

Effect of probiotic supplementation on lipoprotein-associated phospholipase A2 in type 2 diabetic patients: a randomized double blind clinical controlled trial.

Jaff S, Gubari M, Shab-Bidar S, Djafarian K Nutr Metab (Lond). 2024; 21(1):3.

PMID: 38167029 PMC: 10763277. DOI: 10.1186/s12986-023-00778-5.

Fetal High-Density Lipoproteins: Current Knowledge on Particle Metabolism, Composition and Function in Health and Disease.

Stadler J, Wadsack C, Marsche G Biomedicines. 2021; 9(4).

PMID: 33808220 PMC: 8067099. DOI: 10.3390/biomedicines9040349.

SERUM LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN MALES WITH METABOLIC SYNDROME AND OBSTRUCTIVE SLEEP APNEA.

Moise L, Marta D, Rascu A, Moldoveanu E Acta Endocrinol (Buchar). 2019; 14(1):36-42.

PMID: 31149234 PMC: 6516608. DOI: 10.4183/aeb.2018.36.

Maternal Gestational Diabetes Mellitus increases placental and foetal lipoprotein-associated Phospholipase A2 which might exert protective functions against oxidative stress.

Schliefsteiner C, Hirschmugl B, Kopp S, Curcic S, Bernhart E, Marsche G Sci Rep. 2017; 7(1):12628.

PMID: 28974763 PMC: 5626711. DOI: 10.1038/s41598-017-13051-6.

Lipoprotein-associated Phospholipase A2 Is Associated with Risk of Mild Cognitive Impairment in Chinese Patients with Type 2 Diabetes.

Cai R, Huang R, Han J, Sun H, Sun J, Xia W Sci Rep. 2017; 7(1):12311.

PMID: 28951620 PMC: 5615059. DOI: 10.1038/s41598-017-12515-z.

References

Asano K, Okamoto S, Fukunaga K, Shiomi T, Mori T, Iwata M . Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun. 1999; 261(2):511-4. DOI: 10.1006/bbrc.1999.1066. View

Kosaka T, Yamaguchi M, Soda Y, Kishimoto T, Tago A, Toyosato M . Spectrophotometric assay for serum platelet-activating factor acetylhydrolase activity. Clin Chim Acta. 2000; 296(1-2):151-61. DOI: 10.1016/s0009-8981(00)00216-3. View

Unno N, Nakamura T, Kaneko H, Uchiyama T, Yamamoto N, Sugatani J . Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in japan. J Vasc Surg. 2000; 32(2):263-7. DOI: 10.1067/mva.2000.105670. View

Packard C, OReilly D, Caslake M, McMahon A, Ford I, Cooney J . Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000; 343(16):1148-55. DOI: 10.1056/NEJM200010193431603. View

Cieslik K, Abrams C, Wu K . Up-regulation of endothelial nitric-oxide synthase promoter by the phosphatidylinositol 3-kinase gamma /Janus kinase 2/MEK-1-dependent pathway. J Biol Chem. 2000; 276(2):1211-9. DOI: 10.1074/jbc.M005305200. View

Cockerill G, Huehns T, Weerasinghe A, Stocker C, Lerch P, MILLER N . Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation. 2001; 103(1):108-12. DOI: 10.1161/01.cir.103.1.108. View

Abuja P, Albertini R . Methods for monitoring oxidative stress, lipid peroxidation and oxidation resistance of lipoproteins. Clin Chim Acta. 2001; 306(1-2):1-17. DOI: 10.1016/s0009-8981(01)00393-x. View

Kosaka T, Yamaguchi M, Miyanaga K, Mizuno K . Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in more than 3000 healthy Japanese. Clin Chim Acta. 2001; 312(1-2):179-83. DOI: 10.1016/s0009-8981(01)00612-x. View

Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield M . Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 2001; 17:615-75. DOI: 10.1146/annurev.cellbio.17.1.615. View

10.

Macphee C . Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. Curr Opin Pharmacol. 2001; 1(2):121-5. DOI: 10.1016/s1471-4892(01)00024-8. View

11.

Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer A . Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2002; 22(2):300-5. DOI: 10.1161/hq0202.104081. View

12.

Tsimihodimos V, Karabina S, Tambaki A, Bairaktari E, Goudevenos J, Chapman M . Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol. 2002; 22(2):306-11. DOI: 10.1161/hq0202.102918. View

13.

Murakami M, Kudo I . Phospholipase A2. J Biochem. 2002; 131(3):285-92. DOI: 10.1093/oxfordjournals.jbchem.a003101. View

14.

Yamakawa T, Tanaka S, Yamakawa Y, Kamei J, Numaguchi K, Motley E . Lysophosphatidylcholine activates extracellular signal-regulated kinases 1/2 through reactive oxygen species in rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2002; 22(5):752-8. DOI: 10.1161/01.atv.0000015903.02749.71. View

15.

Tan K, Chow W, Ai V, Metz C, Bucala R, Lam K . Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care. 2002; 25(6):1055-9. DOI: 10.2337/diacare.25.6.1055. View

16.

Arai H . Platelet-activating factor acetylhydrolase. Prostaglandins Other Lipid Mediat. 2002; 68-69:83-94. DOI: 10.1016/s0090-6980(02)00023-0. View

17.

Lyons T . Oxidized low density lipoproteins: a role in the pathogenesis of atherosclerosis in diabetes?. Diabet Med. 1991; 8(5):411-9. DOI: 10.1111/j.1464-5491.1991.tb01624.x. View

18.

Hattori K, Hattori M, Adachi H, Tsujimoto M, Arai H, Inoue K . Purification and characterization of platelet-activating factor acetylhydrolase II from bovine liver cytosol. J Biol Chem. 1995; 270(38):22308-13. DOI: 10.1074/jbc.270.38.22308. View

19.

Lopes-Virella M, Virella G . Cytokines, modified lipoproteins, and arteriosclerosis in diabetes. Diabetes. 1996; 45 Suppl 3:S40-4. DOI: 10.2337/diab.45.3.s40. View